Abstract

PHARMACOLOGICAL ADVANCES IN ANTIMALARIAL REMEDY MECHANISMS, RESISTANCE, AND ARISING MEDICINE DELIVERY SYSTEMS

*Arshad Mansuri, Rani Dhurete, Manoj Goyal

ABSTRACT

Malaria remains one of the most significant infectious diseases globally, caused primarily by protozoan parasites of the genus Plasmodium, with Plasmodium falciparum and Plasmodium vivax being the most clinically important species. Despite major advances in prevention and control strategies, malaria continues to impose a substantial burden on public health systems, particularly in tropical and subtropical regions. Recent decades have witnessed remarkable pharmacological advancements in antimalarial therapy, including the development of artemisinin-based combination therapies (ACTs), novel synthetic compounds, and innovative drug delivery systems designed to enhance therapeutic efficacy and overcome resistance. The evolution of antimalarial drugs has been driven by the parasite’s adaptive capacity to develop resistance. Historical drugs such as chloroquine, sulfadoxine-pyrimethamine, and mefloquine once served as frontline treatments but have progressively lost efficacy in many endemic regions due to widespread resistance. This challenge has accelerated research into new pharmacological targets within the parasite’s life cycle, including heme detoxification pathways, mitochondrial electron transport systems, apicoplast metabolism, and parasite-specific enzymes essential for survival and replication. Artemisinin and its derivatives remain the cornerstone of modern malaria treatment due to their rapid parasiticidal activity. However, emerging partial resistance in Southeast Asia and parts of Africa has raised global concern, prompting intensified efforts to develop next-generation antimalarials with improved pharmacokinetic profiles and novel mechanisms of action. Additionally, combination therapies are being optimized to delay resistance development and enhance treatment outcomes. Another significant advancement lies in drug delivery systems, including nanoparticle-based formulations, liposomal encapsulation, solid lipid nanoparticles, and targeted delivery platforms. These technologies aim to improve drug solubility, bioavailability, tissue targeting, and controlled release, thereby increasing therapeutic effectiveness while reducing toxicity. Furthermore, long-acting injectable formulations and oral controlled-release systems are being explored to improve patient compliance in endemic regions. In parallel, vaccine development has gained momentum with the introduction of RTS,S/AS01 and newer candidates like R21/Matrix-M, representing a paradigm shift in malaria prevention strategies. However, pharmacological interventions remain essential due to incomplete vaccine efficacy. This review comprehensively discusses pharmacological advances in antimalarial therapy, emphasizing mechanisms of action, resistance patterns, emerging drug classes, and novel delivery systems. It highlights current challenges and future directions in malaria treatment, aiming to provide a detailed understanding of how modern pharmacology is reshaping malaria control strategies worldwide.

Keywords: Malaria; Plasmodium falciparum; antimalarial drugs; artemisinin-based combination therapy; drug resistance; nanoparticle drug delivery; pharmacological mechanisms; vaccine development; parasite biology; emerging therapies.